PH22481A - N,n-dimethyl-1-/-(4-chlorophenyl) cyclobutyl/-3-methylbuttlamine hydrochloride monhydrate, composition thereof and method of use - Google Patents

N,n-dimethyl-1-/-(4-chlorophenyl) cyclobutyl/-3-methylbuttlamine hydrochloride monhydrate, composition thereof and method of use

Info

Publication number
PH22481A
PH22481A PH34552A PH34552A PH22481A PH 22481 A PH22481 A PH 22481A PH 34552 A PH34552 A PH 34552A PH 34552 A PH34552 A PH 34552A PH 22481 A PH22481 A PH 22481A
Authority
PH
Philippines
Prior art keywords
cyclobutyl
chlorophenyl
dimethyl
methylbuttlamine
monhydrate
Prior art date
Application number
PH34552A
Other languages
English (en)
Inventor
Jeffery James Edward
Whybrow Derek
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10589895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH22481(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of PH22481A publication Critical patent/PH22481A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
PH34552A 1985-12-17 1986-12-04 N,n-dimethyl-1-/-(4-chlorophenyl) cyclobutyl/-3-methylbuttlamine hydrochloride monhydrate, composition thereof and method of use PH22481A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Publications (1)

Publication Number Publication Date
PH22481A true PH22481A (en) 1988-09-12

Family

ID=10589895

Family Applications (1)

Application Number Title Priority Date Filing Date
PH34552A PH22481A (en) 1985-12-17 1986-12-04 N,n-dimethyl-1-/-(4-chlorophenyl) cyclobutyl/-3-methylbuttlamine hydrochloride monhydrate, composition thereof and method of use

Country Status (34)

Country Link
US (2) US4929629A (fr)
EP (1) EP0230742B1 (fr)
JP (1) JPS62155240A (fr)
KR (1) KR940008913B1 (fr)
CN (1) CN1016245B (fr)
AT (1) ATE56942T1 (fr)
AU (1) AU601167B2 (fr)
CA (1) CA1266278A (fr)
CS (1) CS259545B2 (fr)
DD (1) DD263050A5 (fr)
DE (1) DE3674570D1 (fr)
DK (1) DK170770B1 (fr)
EG (1) EG17770A (fr)
ES (1) ES2018163T4 (fr)
FI (1) FI90413C (fr)
GB (1) GB8531071D0 (fr)
GE (1) GEP19970812B (fr)
GR (1) GR3001069T3 (fr)
HU (1) HU201901B (fr)
IE (1) IE59429B1 (fr)
IL (1) IL80934A (fr)
IN (1) IN163129B (fr)
LU (1) LU90865I2 (fr)
MX (1) MX4684A (fr)
NL (1) NL300065I1 (fr)
NO (2) NO165540C (fr)
NZ (1) NZ218578A (fr)
PH (1) PH22481A (fr)
PL (1) PL149519B1 (fr)
PT (1) PT83958B (fr)
SU (1) SU1443796A3 (fr)
UA (1) UA7206A1 (fr)
YU (1) YU46033B (fr)
ZA (1) ZA869078B (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JPH07508281A (ja) * 1992-06-23 1995-09-14 セプラコア　インコーポレーテッド 光学的に純粋な（＋）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
JPH08500093A (ja) * 1992-06-23 1996-01-09 セプラコア インコーポレーテッド 光学的に純粋な（−）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE4443891A1 (de) 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
MXPA01007388A (es) * 1999-01-20 2002-07-22 Knoll Gmbh Metodo para ayudar a dejar de fumar.
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
WO2000056321A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Traitement de l'hyperactivite
US6376553B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Treatment of pain
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
AU3895400A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Control of metabolism
WO2000056310A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Traitement du syndrome de fatigue chronique
WO2000056319A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Traitement de l'hypotension orthostatique
KR20020038567A (ko) * 1999-03-19 2002-05-23 독터. 호르스트 하스칼, 잉에 린스 골관절염의 치료방법
DE60019914T2 (de) 1999-03-19 2006-05-04 Abbott Gmbh & Co. Kg Verwendung von Sibutramin oder dessem Derivat zur Behandlung von Schlafstörungen
WO2000056308A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention de maladies cardio-vasculaires
AU3632000A (en) * 1999-03-19 2000-10-09 Abbott Gmbh & Co. Kg Treatment of certain cancers associated with weight gain
AU3894600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating sexual dysfunction
JP2002539250A (ja) 1999-03-19 2002-11-19 クノール・ゲー・エム・ベー・ハー 肺高血圧症の治療
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
WO2002083631A1 (fr) * 2001-04-13 2002-10-24 Sepracor Inc. Procedes permettant la preparation de didesmethylsibutramine et d'autres derives de sibutramine
ATE486842T1 (de) * 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
BR0315084A (pt) * 2002-10-05 2005-08-16 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo hemiidrato cristalino de metanossulfonato de sibutramina
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
ATE439347T1 (de) * 2004-11-23 2009-08-15 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
JP2008526836A (ja) 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション シブトラミンの無機酸塩
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
JP2009503050A (ja) * 2005-08-04 2009-01-29 ファイザー・リミテッド ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
EP1938811A4 (fr) * 2005-09-22 2008-12-17 Eisai R&D Man Co Ltd Préparation thérapeutique pour le traitement de la boulimie et de la dépression associée à la boulimie
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007096763A2 (fr) * 2006-02-23 2007-08-30 Pfizer Limited Pipéridinoylpyrrolidines en tant qu'agonistes du récepteur de la mélanocortine de type 4
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
JP2010503709A (ja) 2006-09-15 2010-02-04 レビバ ファーマシューティカルズ，インコーポレーテッド シクロアルキルメチルアミンの合成、使用方法および組成物
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
AU2007320906A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
EP2099755A2 (fr) * 2006-11-20 2009-09-16 Glenmark Pharmaceuticals S.A. Dérivés d'acétylène comme inhibiteurs de la stéaroyl coa désaturase
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
WO2008124120A1 (fr) * 2007-04-09 2008-10-16 Scidose, Llc Combinaisons de statines et d'agent anti-obésité
WO2009037542A2 (fr) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Composés spirocycliques en tant qu'inhibiteurs de stéaroyle coa désaturase
DK2326638T5 (da) * 2008-08-06 2014-01-13 Pfizer Ltd Diazepin- og diazocan-forbindelser som mc4-agonister
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2395987A1 (fr) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Utilisation d'une combinaison de diazoxyde et de metformine pour le traitement de l'obésité ou des troubles liés à l'obésité
ES2527179T3 (es) 2009-11-02 2015-01-21 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
WO2011122524A1 (fr) 2010-03-29 2011-10-06 アステラス製薬株式会社 Composition pharmaceutique à libération contrôlée
MX2012015102A (es) 2010-07-06 2013-05-01 Astrazeneca Ab Agentes terapeuticos 976.
PT2637646T (pt) 2010-11-08 2016-08-17 Albireo Ab Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar
HUE030062T2 (en) 2010-11-08 2017-04-28 Albireo Ab IBAT inhibitors for the treatment of liver diseases
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CA2922849A1 (fr) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents utiles pour le traitement de l'obesite, du diabete et de troubles associes
CN110372522B (zh) * 2019-07-30 2020-10-02 南京工业大学 一种从含有戊二胺的固相中汽提回收戊二胺的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
NO165540B (no) 1990-11-19
KR870005961A (ko) 1987-07-08
ES2018163T4 (es) 2012-06-14
GR3001069T3 (en) 1992-03-20
LU90865I2 (fr) 2002-02-18
CS259545B2 (en) 1988-10-14
FI865030A0 (fi) 1986-12-10
PL149519B1 (en) 1990-02-28
AU601167B2 (en) 1990-09-06
IL80934A (en) 1990-07-26
DE3674570D1 (de) 1990-10-31
EG17770A (en) 1991-03-30
IE863102L (en) 1987-06-17
PL263020A1 (en) 1988-05-12
NO2005022I1 (no) 2005-10-03
JPH0144176B2 (fr) 1989-09-26
AU6644286A (en) 1987-06-18
EP0230742B1 (fr) 1990-09-26
PT83958B (pt) 1989-05-12
NO165540C (no) 1991-02-27
GB8531071D0 (en) 1986-01-29
GEP19970812B (en) 1997-02-10
ATE56942T1 (de) 1990-10-15
DK585786A (da) 1987-06-18
UA7206A1 (uk) 1995-06-30
PT83958A (en) 1987-01-01
US5068440A (en) 1991-11-26
DD263050A5 (de) 1988-12-21
IN163129B (fr) 1988-08-13
FI90413C (fi) 1994-02-10
HUT45964A (en) 1988-09-28
FI865030A (fi) 1987-06-18
HU201901B (en) 1991-01-28
DK585786D0 (da) 1986-12-05
MX4684A (es) 1993-12-01
FI90413B (fi) 1993-10-29
IE59429B1 (en) 1994-02-23
ES2018163B3 (es) 1991-04-01
JPS62155240A (ja) 1987-07-10
NO865093L (no) 1987-06-18
DK170770B1 (da) 1996-01-15
NL300065I1 (nl) 2001-12-01
CN1016245B (zh) 1992-04-15
KR940008913B1 (ko) 1994-09-28
EP0230742A1 (fr) 1987-08-05
CA1266278A (fr) 1990-02-27
ZA869078B (en) 1987-07-29
SU1443796A3 (ru) 1988-12-07
US4929629A (en) 1990-05-29
CS930586A2 (en) 1988-02-15
NZ218578A (en) 1989-04-26
YU205086A (en) 1987-12-31
YU46033B (sh) 1992-12-21
CN86108547A (zh) 1987-08-19
NO865093D0 (no) 1986-12-16

Similar Documents

Publication Publication Date Title
PH22481A (en) N,n-dimethyl-1-/-(4-chlorophenyl) cyclobutyl/-3-methylbuttlamine hydrochloride monhydrate, composition thereof and method of use
CA2003524A1 (fr) Traitement de l'obesite
NZ212067A (en) Derivatives of glycerophosphocholine and glycerophosphoethanolamine; preparation and use
ES542430A0 (es) Un procedimiento para la preparacion de una composicion antiacida de alginato de magnesio.
NZ230356A (en) 2',3'-dideoxy-5-ethynyl-3'-fluorouridine: preparatory processes and pharmaceutical compositions
GB2184122B (en) N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GR3001862T3 (en) Pharmaceutical preparation for tinea pedis
ES8702142A1 (es) Procedimiento para preparar un medicamento a base de 2-amino-3-carboetoxiamino-6-(4-fluoro-bencilamino)-piridina y 4-acetamido-fenol
IT8468196A1 (it) Dispositivo osmotico e procedimento per l'erogazione di un agente benefico, particolarmente di un farmaco ad un ambiente d'uso.
IL71176A (en) Analgesic preparation containing tizanidine and paracetamol
HUT41817A (en) Process for preparing p-/acyl-amino/-benzamides
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
PH24690A (en) 8 alpha(-acylaminoergoline, pharmaceutical composition containing said compound and method of use thereof
DK162086A (da) Laegemiddel indeholdende vaevs-plasminogenaktivator, dets fremstilling og anvendelse
DK222988D0 (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
IL103313A (en) Pharmaceutical compositions comprising a tramadol material and acetaminophen